Clinical trials: Empagliflozin
Insulin Resistance - Type A, Insulin Resistance - Type B
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-02 (NCT04221152)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Patients
Drug Interaction Study Between Dorzagliatin and Empagliflozin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM.
- Trial name
- NCT03790787
- Testing
- Empagliflozin, Dorzagliatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hua Medicine Limited
Healthy
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Bioequivalence of two 12.5 mg empagliflozin/500 mg metformin fixed dose combination tablets compared to the free combination of empagliflozin 25 mg and metformin 1000 mg in healthy male and female volunteers under fed conditions
- Trial name
- NCT02577315
- Testing
- Empagliflozin, Metformin
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Kidney Stones
SGLT2i in Kidney Stones
This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation.
- Trial name
- NCT07055282
- Testing
- Empagliflozin (Jardiance®)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Postprandial Hypoglycemia, Bariatric Surgery
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
The purpose of the study is to investigate whether hypoglycaemia observed after food intake in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via inhibition of inflammation with an human…
- Conditions
- Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping Syndrome
- Trial name
- Hypo-BEAR (NCT03200782)
- Testing
- Empagliflozin, Anakinra
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Kidney Disease
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or…
- Trial name
- NCT06926660
- Testing
- Vicadrostat, Empagliflozin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 492 people
- Sponsor
- Boehringer Ingelheim
Heart Failure Acute, Ventilator Lung
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
This study will explore the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing cardiac ischemia and cardiopulmonary edema in patients with acute decompensated heart failure during weaning from…
- Trial name
- NCT06142474
- Testing
- SGLT2 inhibitor
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Coronary Artery Disease, Atherosclerosis
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions.
- Conditions
- Coronary Artery Disease, Atherosclerosis, Heart Attack
- Trial name
- ARTCAP (NCT06280976)
- Testing
- Statin, Aspirin tablet, Nexlizet
- Where
- United States
- Sponsor
- University of Louisville
Overweight Subject, Healthy Subjects
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects.
- Trial name
- NCT07331389
- Testing
- Metformin, Empagliflozin, Midazolam
- Where
- China
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Type 2
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2…
- Trial name
- EMPOWER (NCT07771010)
- Testing
- Empagliflozin (Jardiance®), Metformin, Synjardy® 12.5mg/1000mg film-coated tablets
- Where
- Slovenia
- Volunteers
- 54 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
The goal of this low-intervention clinical trial is to learn about the effect of the drug Empagliflozin in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT06046612
- Testing
- Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Maastricht University Medical Center
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Hypertension (HTN)
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with…
- Trial name
- NCT07678151
- Testing
- Empagliflozin and Finerenone
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Heart Health Research Center
Heart Failure With Reduced Ejection Fraction
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
Research hypothesis: Fast telemonitored medical sequencing in patients with heart failure with reduced ejection fraction (HFrEF) is safe and feasible.
- Trial name
- TELE-FASTER (NCT05637853)
- Testing
- GDMT
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Göteborg University
Moderate Aortic Valve Stenosis
The Role of SGLT2i in Management of Moderate AS
Background: The aortic valve is like a door in the heart that lets blood flow out to the body. Over time, this valve can get worn out and become too narrow, leading to a condition called aortic stenosis.
- Trial name
- NCT06469645
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University of East Anglia
Type1diabetes
Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin
One of the challenges in the design of the artificial pancreas (AP) is preventing postprandial hyperglycemia. Beyond algorithmic solutions, one countermeasure to postprandial hyperglycemia that may enhance performance of the AP…
- Trial name
- CLASS15 (NCT03510000)
- Testing
- Empagliflozin 25mg, Single hormone artificial pancreas, Meal strategies
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Acute Decompensated Heart Failure (ADHF)
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared…
- Trial name
- EMPA-CON (NCT07038356)
- Testing
- Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- 12 sites in Germany
- Volunteers
- 536 people
- Sponsor
- Christian Schulze
HIV-1-infection, Coronary Microvascular Dysfunction
Improving Coronary Vascular Health in Women
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may…
- Conditions
- HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
- Trial name
- INFORM_2 (NCT06843902)
- Testing
- Health Education, Subspecialty clinic referral
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim